Job vacancy in Biocon limited walk-in interview on 5th may 2024

Biocon Limited is an Indian biopharmaceutical company based in Bangalore. It was founded by Kiran Mazumdar-Shaw in 1978. The company manufactures generic active pharmaceutical ingredients (APIs) that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics as well as biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon’s biosimilar products are also sold in both bulk and formulation forms in several emerging markets.

Biocon’s formulations for the Indian market include metabolics, oncology, immunotherapy and nephrology products. Some of Biocon’s key brands in India include INSUGEN (rh-insulin), BASALOG (Glargine), BIOMAb EGFR (Nimotuzumab), BLISTO (Glimepiride + Metformin), CANMAb (Trastuzumab), Evertor (Everolimus), TACROGRAF (Tacrolimus), ALZUMAb (Itolizumab) and KRABEVA (Bevacizumab).Syngene International Limited (Syngene) is a publicly listed subsidiary of Biocon, operating in the contract research and development organization.Biocon was founded in 1978 with Rs.10,000 as the initial capital by a Kiran Mazumdar who was born to Gujarati parents in Bangalore.In 1979 Biocon Became the first Indian company to manufacture and export enzymes to the US and Europe.In 1989 Unilever acquired Biocon Biochemicals Ltd. in Ireland and merges it with its subsidiary, Quest International; Biocon receives US funding for proprietary technologies.In 1994 Biocon established Syngene International as a Custom Research Company (CRC).During 1998 Unilever agrees to sell its shareholding in Biocon to the Indian promoters. Biocon becomes an independent entity.In 2001 Biocon became the first Indian company to be approved by USFDA for the manufacture of lovastatin; PlaFractor is granted a US 2001 and worldwide patent.

More about company

http://www.biocon.com/docs/Biocon_Annual_Report_2017.pdf

Biocon limited, we are looking for dynamic individuals seeking to elevate their careers in the pharmaceutical industry.

Walk-in interview details –

Day and date – 5th May 2024 Sunday

Time – 9:00 Am to 2:00 Pm

Venue – Hotel lemon tree premier , HITEC city , Madhapur, Hyderabad 500081 Telangana

In 2003 Biocon becomes the first company worldwide to develop human insulin on a Pichia expression system.During 2006 BIOMAb EGFR, first indigenously developed humanised monoclonal antibody for head-and-neck cancer is launched and APJ Abdul Kalam inaugurates India’s Largest Biotech-Hub “Biocon Park”.In 2008 Biocon acquires a 70% stake in German pharmaceutical company, AxiCorp GmbH.During 2009 Syngene-Bristol Myers Squibb research facility is established in Bengaluru.Later during 2009 Mylan announced strategic collaboration with Biocon to Enter the Global Generic Biologics Market.In 2010 Biocon expanded to Malaysia, biopharmaceutical manufacturing and R&D facility established in Iskandar Malaysia, Johor.In 2012 Abbott announces collaboration with Syngene to Open First Nutrition R&D Center in India.

During 2013 Biocon launched biologic drug ALZUMAb to treat psoriasis.During 2014 Biocon launched the first biosimilar drug CANMAb to treat breast cancer.In 2015 Biocon launched hepatitis-C drug in India under brand name CIMIVIR-L. In 2016, Biocon Became the first Indian company to launch a biosimilar Insulin Glargine pen in Japan.During 2016, Syngene set up Amgen R&D center in Bangalore.In 2017, Biocon’s Insugen became the first locally manufactured biosimilar product to be approved for sale by the Malaysian drug regulator.In 2017, USFDA approves Mylan-Biocon’s biosimilar for cancer drug Herceptin.During 2018, Biocon, Mylan get European Commission approval to market biosimilar insulin glargine.During 2021 Biocon Biologics and Serum Institute of India formed a joint agreement to commercialise vaccines, biological drugs, and antibody therapies together. Another aspect of the deal involves Bicocon selling 15% of its biologics subsidiary to Serum Institute of India, in return for Biocon gaining access to 100 million annual doses of vaccines for a 15-year period.During 2022, Biocon Biologics bought the biosimilar assets of Viatris, for $3.34 billion.

Job description –

Department – Regulatory affairs

Experience – 03 to 12 years

Qualification – B pharmacy/ M pharmacy/ MSC

Job location – Bengaluru

Note –

Intrested candidates can email their resume to upendra.kamma@biocon.com or rashmi.gupta@biocon.com for an interview opportunity .

Candidates must carry their updated resume, certificates of their highest qualification, latest incremental letter and last 3 months payslip .

For more job related updates joined WhatsApp group

https://chat.whatsapp.com/KCk1lRtEdlJEJYDBTQNc9i

Job vacancy in Biocon limited walk-in interview on 5th may 2024